BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31523839)

  • 21. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
    Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
    Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systemic mastocytosis associated with essential thrombocythemia.
    Dobrea C; Ciochinaru M; Găman A; Dănăilă E; Coriu D
    Rom J Morphol Embryol; 2012; 53(1):197-202. PubMed ID: 22395523
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Long B; Shi H; Zhu C
    Hematology; 2020 Dec; 25(1):283-285. PubMed ID: 32657243
    [No Abstract]   [Full Text] [Related]  

  • 24. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge.
    Horny HP; Sotlar K; Sperr WR; Valent P
    J Clin Pathol; 2004 Jun; 57(6):604-8. PubMed ID: 15166264
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
    Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
    J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mastocytosis and related disorders.
    Chiu A; Orazi A
    Semin Diagn Pathol; 2012 Feb; 29(1):19-30. PubMed ID: 22372203
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KIT D816V mutation detection: a comparative study using peripheral blood, bone marrow aspirate and bone marrow trephine samples for detection of KIT mutations in patients with systemic mastocytosis.
    Agarwal R; McBean M; Hewitt C; Westerman DA
    Leuk Lymphoma; 2014 Sep; 55(9):2202-3. PubMed ID: 24359244
    [No Abstract]   [Full Text] [Related]  

  • 28. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
    Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
    J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Splenic mastocytosis: report of two cases and detection of the transforming somatic C-KIT mutation D816V.
    Wimazal F; Schwarzmeier J; Sotlar K; Simonitsch I; Sperr WR; Fritsche-Polanz R; Födinger M; Schubert J; Horny HP; Valent P
    Leuk Lymphoma; 2004 Apr; 45(4):723-9. PubMed ID: 15160946
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of sensitive KIT D816V detection on recognition of indolent Systemic Mastocytosis.
    De Matteis G; Zanotti R; Colarossi S; De Benedittis C; Garcia-Montero A; Bonifacio M; Sartori M; Aprili F; Caruso B; Paviati E; Carli G; Perbellini O; Zamò A; Bonadonna P; Pizzolo G; Guidi G; Martinelli G; Soverini S
    Leuk Res; 2015 Mar; 39(3):273-8. PubMed ID: 25582384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detection of KIT D816V in peripheral blood of children with manifestations of cutaneous mastocytosis suggests systemic disease.
    Carter MC; Bai Y; Ruiz-Esteves KN; Scott LM; Cantave D; Bolan H; Eisch R; Sun X; Hahn J; Maric I; Metcalfe DD
    Br J Haematol; 2018 Dec; 183(5):775-782. PubMed ID: 30488427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms.
    Boiocchi L; Hasserjian RP; Pozdnyakova O; Wong WJ; Lennerz JK; Le LP; Dias-Santagata D; Iafrate AJ; Hobbs GS; Nardi V
    Hum Pathol; 2019 Apr; 86():1-11. PubMed ID: 30594750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis.
    Edahiro Y; Ochiai T; Hashimoto Y; Morishita S; Shirane S; Inano T; Furuya C; Koike M; Noguchi M; Usuki K; Shiratsuchi M; Nakajima K; Ohtsuka E; Tanaka H; Kawata E; Nakamae M; Ueda Y; Aota Y; Sugita Y; Ohara S; Yamasaki S; Asagoe K; Yoshida S; Yamanouchi J; Suzuki S; Kondo T; Kanisawa Y; Toyama K; Omura H; Mizuchi D; Sakamaki S; Ando M; Komatsu N
    Int J Hematol; 2023 Jul; 118(1):47-53. PubMed ID: 37058247
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations.
    Pullarkat VA; Bueso-Ramos C; Lai R; Kroft S; Wilson CS; Pullarkat ST; Bu X; Thein M; Lee M; Brynes RK
    Am J Hematol; 2003 May; 73(1):12-7. PubMed ID: 12701114
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN with RS-T) complicated by hyperleukocytosis and gene analysis in relation to leukocytosis.
    Aoyama Y; Sakai K; Kodaka T; Tsunemine H; Nishio K; Itoh T; Inoue D; Takahashi T
    J Clin Exp Hematop; 2019 Mar; 59(1):29-33. PubMed ID: 30726782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis.
    Greiner G; Gurbisz M; Ratzinger F; Witzeneder N; Class SV; Eisenwort G; Simonitsch-Klupp I; Esterbauer H; Mayerhofer M; Müllauer L; Sperr WR; Valent P; Hoermann G
    Haematologica; 2020; 105(2):366-374. PubMed ID: 31018976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Revisiting diagnostic criteria for myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Borderline cases without anemia exist.
    Li P; Shahmarvand N; Lynch D; Gotlib JR; Merker JD; Zehnder JL; George TI; Ohgami RS
    Int J Lab Hematol; 2019 Jun; 41(3):345-352. PubMed ID: 30811101
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis: Ringing in a new future.
    Nathan DI; Feld J; El Jamal SM; Mascarenhas J; Tremblay D
    Leuk Res; 2022 Apr; 115():106820. PubMed ID: 35279478
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay.
    Kristensen T; Vestergaard H; Møller MB
    J Mol Diagn; 2011 Mar; 13(2):180-8. PubMed ID: 21354053
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S; Zhang Y; Hugonin C; Mangean MD; He L; Wedeh G; Launay JM; Van Rijn S; Würdinger T; Louache F; Arock M
    Oncotarget; 2016 Dec; 7(50):82985-83000. PubMed ID: 27783996
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.